CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 175 enrolled
Drug / intervention
Rosuvastatin 20mgdrug
Likely dose
Rosuvastatin 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06105060
NCT06105060Early Ph 1Completed
CompareCT.gov

Clinical and Biochemical Study of the Effects of Rosuvastatin, Vitamin E, and N-Acetyl Cysteine on Patients With Non-alcoholic Steatohepatitis: a Randomized Controlled Trial

Beni-Suef University·interventional·Posted Oct 27, 2023·Updated Feb 6, 2025

In Brief

A Early Phase 1 clinical trial evaluating Rosuvastatin 20mg for Non-alcoholic Steatohepatitis. Completed, enrolled 175 participants across 1 site.

Detailed Summary

This study aims to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH. The primary endpoint of this 6-month study would be an improved degree of fibrosis with no worsening of NASH or NASH resolution with no worsening of fibrosis and steatosis that the study considered successful if either 1ry endpoint is met. The secondary endpoint of this study is the improvement of biochemical markers related to steatosis, inflammation, oxidative stress, insulin resistance, and liver fibrosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Steatohepatitis
CountriesEgypt
Collaborators--

Timeline

Early Ph 1CompletedFinished
202420252026
First PostedOct 27, 2023
Enrollment StartDec 17, 2023
Primary CompletionJun 17, 2024
Study CompletionJun 27, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.7 years ago

Interventions

Rosuvastatin 20mgdrug

to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.